Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > October 31, 2022
Daily News
October 31, 2022
- Researchers Launch Scientific Society for Oncolytic Virus Therapies
October 31, 2022
- MHLW Panel Puts Pfizer’s Precedex on Hold for Pediatric Indication
October 31, 2022
- Deloitte Proposes Pricing Schemes to Encourage Consolidation of Generic Makers
October 31, 2022
- Aricept’s Lewy Body Dementia Indication to Be Modified after Post-Launch Trial Miss
October 31, 2022
- Novartis Challenges US Court Verdict on Tafinlar Patent Infringement
October 31, 2022
- Kyowa Kirin Files Hyperphosphatemia Drug in Japan
October 31, 2022
- Hisamitsu’s Osteoarthritis Patch Drug Fails in US PIII Study
October 31, 2022
- Opdivo Snags South Korea Nod for Neoadjuvant Use in NSCLC
October 31, 2022
- MHLW Panel OKs 100 More Health Damage Claims for COVID-19 Vaccines
October 31, 2022
- JPMA Applauds Drug Discovery Startup Support in New Economic Package
October 31, 2022
- Japan Adopts Stimulus Package, Set to Support Domestic API Production
October 31, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…